Lithium, as a neuroprotective therapy for Alzheimer’s disease pathology, modifies abeta plaque toxicity by Trujillo-Estrada, Laura et al.
LITHIUM, AS A NEUROPROTECTIVE THERAPY FOR 
ALZHEIMER’S DISEASE PATHOLOGY, MODIFIES ABETA 
PLAQUE TOXICITY 
 
 
L. Trujillo-Estrada1, V. De Castro1, S. Jimenez2, R. Sanchez-Varo1, E. Sanchez-
Mejias1, V. Navarro2, M. Vizuete2, JC Davila1, J. Vitorica2 and A. Gutierrez1.  
 
1 Department of Cell Biology, Genetics and Physiology, Faculty of Sciences, University 
of Malaga. CIBERNED. IBIMA. Malaga, Spain. 
2 Department of Biochemistry & Molecular Biology, Faculty of Pharmacy, University of 
Seville. CIBERNED. IBIS. Seville, Spain. 
 
BACKGROUND: Despite the relatively large information about the Alzheimer’s disease 
(AD) pathology, no effective disease-modifying treatment has been yet developed. 
Lithium, a primary drug to treat bipolar disorder, has been suggested as a potential 
treatment against AD. In this work we have evaluated whether lithium treatment could 
ameliorate the neuropathology progression of the transgenic PS1M146L/APPSwe-
London mice. Unlike most transgenic animal models, which do not exhibit the 
neurodegenerative spectrum of disease observed in the patient population, this AD 
model exhibits a prominent amyloid pathology along with a selective and significant 
neuronal loss in the hippocampus and entorhinal cortex. Therefore, this model is highly 
valuable for evaluating the effectiveness of potential neuroprotective therapies for AD. 
 
METHODS: For lithium treatment, PS1/APP mice (3 month old at the beginning of 
treatment) were fed, ad libitum, with diet supplemented with lithium carbonate (1.2g/kg, 
Harlan, Spain). The treatment lasts 6 months. After behavioural studies, mice were 
anesthetized and brains dissected out (hippocampus and cortex). Hemibrains were 
processed for immunohistochemistry, stereological and image analysis quantification, 
and the other hemibrains for RT-PCR and Western blot studies. 
 
RESULTS: Our data demonstrate that chronic oral administration of lithium, before the 
pathology onset, resulted in less toxic plaque formation that significantly ameliorated 
the degenerative processes and behavioural/memory deficits occurring during disease 
progression in our PS1/APP model. Specifically, and of great relevance for AD 
prevention, early lithium intervention was able to arrest neuronal loss in hippocampus 
and entorhinal cortex of highly vulnerable populations. Besides, lithium reduced the 
axonal dystrophic pathology, associated to amyloid plaques, by increasing the Abeta 
compaction. Moreover, a significant lower accumulation of phospho-tau, LC3-II and 
ubiquitinated proteins was detected. Our study highlights that the switch of plaque 
quality by lithium could be mediated by astrocyte activation and the release of heat 
shock proteins, which concentrated in the core of the plaques.  
 
CONCLUSIONS: Our data demonstrate a novel lithium-mediated mechanism capable 
of altering the course of the disease in an amyloidogenic AD model. This 
pharmacological in vivo modulation of the extracellular Abeta plaque 
compaction/toxicity might represent an innovative therapeutic approach for AD. 
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